| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Delivering answers with impact
To provide physicians and healthcare professionals a deeper understanding of how our testing approach helps ensure the right patient receives the right test at the right time, we’ve developed an educational resource with insights from the Mayo Clinic peripheral neuropathy experts who are on the leading edge of test development.
Our e-book is essential reading for healthcare professionals on the front lines of diagnosing and caring for patients impacted by this complex condition.
Download now
Fill out the form to download our e-book, "Peripheral neuropathy: Cutting through diagnostic dissonance with an algorithmic approach."
“We’re pretty confident that these tests and the algorithms are faithful to our belief in getting the right patient to the right test — that is a very important concept and by doing that, we can get patients to the best care.”
Christopher Klein, M.D., Mayo Clinic neurologist and neuromuscular specialist
The collaborative underpinning of innovation
The integration between the clinical practice and test developers at Mayo Clinic is the engine powering innovation at Mayo Clinic Laboratories. Through close collaboration with neurologists, neuromuscular specialists, geneticists, and other clinical experts, the most important clinical questions are woven into leading-edge testing.
This multidisciplinary, patient-first approach not only aligns with Mayo Clinic’s core values, it also centers test development on the implementation of novel approaches that elevate patient care.
Highlights
After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP
Justin Fugelsang and Zach Pedowitz have never met. Yet both young men were diagnosed with a rare form of Charcot-Marie-Tooth disease, called sorbitol dehydrogenase (SORD) deficiency, and both found clarity through Mayo Clinic Laboratories' innovative SORD testing. Their journeys inspire resilience, as Justin has channeled his emotions into guitar playing, and Zach has embraced educational leadership.
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.